Chinese vaccine and biologic products developer and manufacturer Shenzhen Kangtai Biological Products has announced the pricing for an initial public offering (IPO) of shares to raise ¥138.2m ($20.08m) in gross proceeds.
The IPO includes 42 million shares priced at ¥3.29 ($0.48) a share, which will be listed in the Shenzhen Stock Exchange.
Go deeper with GlobalData
Australian biopharmaceutical company Telix Pharmaceuticals and French biotechnology company Atlab Pharma SAS will manufacture clinical material and jointly execute a multi-centre Phase IIb trial for the treatment of men with metastatic prostate cancer, with and without end-stage chemotherapy.
The two companies have reached an agreement for the same and intend to conclude therapeutic product development for prostate cancer through the partnership.
German healthcare company Fresenius SE & Co. subsidiary Fresenius Finance Ireland has completed three private placements of unsecured notes in order to fund the acquisition of Quironsalud, and for general corporate purposes.
Two of the placements included 1.5% and 0.87% unsecured notes due 2024 and 2022 respectively, for gross proceeds of €700m ($742.54m) each, while the third one included 3% unsecured notes due in 2032 for gross proceeds of €500m ($530.4m).
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataInvetech and Erytech Pharma have partnered to develop scalable automated manufacturing systems to enable the commercial-scale manufacture of products based on ERYCAPS, a proprietary technology platform owned by the latter.
Australian-based Invetech develops cGMP manufacturing solutions for cell and advanced therapies. Erytech Pharma is a biopharmaceutical company based in France.
US-based Braeburn Pharmaceuticals has announced an IPO to raise gross proceeds of $138.46m.
The offering includes 7.6 million shares of its common stock priced at a minimum of $18 a share. The maximum price is fixed at $21 a share, which will result in gross proceeds of $1.6m.
Underwriters have been granted a 30-day option to purchase an additional 1.1 million shares to cover over-allotments, if any.
